Literature DB >> 2449564

The effectiveness of inotropic agents in isolated cardiac preparations from the human heart.

E Erdmann1.   

Abstract

This review analyses the present knowledge on differences in human and animal heart preparations in respect to positive inotropic stimulation. The pharmacological effects of new positive inotropic drugs usually are evaluated in cardiac preparations from healthy and young animals. Human myocardium, especially from patients with heart failure has, however, distinctly different properties in respect to the positive inotropic effectiveness of several agents. This fact prohibits the extrapolation of results of experiments in laboratory animals to the diseased human heart. The partial ineffectiveness of several established positive inotropic substances in papillary muscles from failing human hearts indicates a membrane defect not present in healthy animal myocardium.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2449564     DOI： 10.1007/bf01735205

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  15 in total

Review 1.  Biochemical, structural and mechanical defects of the failing myocardium.

Authors:  W H Newman
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

Review 2.  Beta-adrenergic function in heart muscle disease and heart failure.

Authors:  M R Bristow; N E Kantrowitz; R Ginsburg; M B Fowler
Journal:  J Mol Cell Cardiol       Date:  1985-07       Impact factor: 5.000

3.  Tolerance to dobutamine after a 72 hour continuous infusion.

Authors:  D A Unverferth; M Blanford; R E Kates; C V Leier
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

4.  Hypertrophic cardiomyopathy characterised by beta-adrenoceptor density, relative amount of beta-adrenoceptor subtypes and adenylate cyclase activity.

Authors:  S Golf; E Myhre; M Abdelnoor; D Andersen; V Hansson
Journal:  Cardiovasc Res       Date:  1985-11       Impact factor: 10.787

5.  Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1986-08-01

6.  Alterations in cardiac alpha and beta adrenoceptors during the development of spontaneous hypertension.

Authors:  S Yamada; T Ishima; T Tomita; M Hayashi; T Okada; E Hayashi
Journal:  J Pharmacol Exp Ther       Date:  1984-02       Impact factor: 4.030

7.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts.

Authors:  M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson
Journal:  N Engl J Med       Date:  1982-07-22       Impact factor: 91.245

8.  Myocardial performance and extracellular ionized calcium in a severely failing human heart.

Authors:  R Ginsburg; L J Esserman; M R Bristow
Journal:  Ann Intern Med       Date:  1983-05       Impact factor: 25.391

Review 9.  Inotropic drugs and their mechanisms of action.

Authors:  H Scholz
Journal:  J Am Coll Cardiol       Date:  1984-08       Impact factor: 24.094

10.  Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors.

Authors:  K A Neve; P B Molinoff
Journal:  Am J Cardiol       Date:  1986-04-25       Impact factor: 2.778
View more
  8 in total

1.  Myocardial beta-adrenoceptor density and the distribution of beta 1- and beta 2-adrenoceptor subpopulations in children with congenital heart disease.

Authors:  R Kozlik; H H Kramer; H Wicht; A Krian; J Ostermeyer; D Reinhardt
Journal:  Eur J Pediatr       Date:  1991-04       Impact factor: 3.183

2.  Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors:  H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

Review 3.  [Histamine effects on the heart with special reference to cardiac side effects of H2 receptor antagonists].

Authors:  D Baller; H Huchzermeyer
Journal:  Klin Wochenschr       Date:  1989-08-01

Review 4.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

5.  Noradrenaline-induced desensitization in cultured heart cells as a model for the defects of the adenylate cyclase system in severe heart failure.

Authors:  C Reithmann; K Werdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989 Jan-Feb       Impact factor: 3.000

6.  Positive inotropic stimulation in the normal and insufficient human myocardium.

Authors:  E Erdmann; M Böhm
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

Review 7.  Phosphodiesterase III inhibitors: long-term risks and short-term benefits.

Authors:  J M Cruickshank
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

8.  Hypertrophic cardiomyopathy: a desensitized cardiac beta-adrenergic system in the presence of normal plasma catecholamine concentrations.

Authors:  C Schumacher; H Becker; R Conrads; U Schotten; S Pott; M Kellinghaus; M Sigmund; F Schöndube; C Preusse; H D Schulte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.